Exciva
Heidelberg
About Exciva
Exciva develops clinical-stage biopharmaceutical therapies focused on addressing neuropsychiatric symptoms associated with dementia, including agitation and aggression in Alzheimer’s disease. It applies a targeted drug rescue approach that identifies and repurposes previously approved or clinically tested compounds into new therapeutic candidates. Exciva conducts scientific research and clinical studies to evaluate safety and potential effectiveness of its investigational products in neuropsychiatry. Its programs include formulations and methods designed for symptomatic relief and improved behavioral outcomes. Exciva collaborates with scientific and medical professionals to advance its pipeline through regulated trial phases and regulatory processes.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $69.8M
- Funding stage: Early Stage Venture
- Last round: Series B (Jan 2026)
- Website: exciva.com
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/exciva-3016 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.